OBJECTIVE: To investigate the associations of endogenous testosterone with prostate growing disorders (PGD) including benign prostatic hyperplasia (BPH) and prostate cancer (PCA). METHODS: The study population was composed by 1176 cases including 371 BPH subjects (31.5%) without cancer who underwent prostate transurethral resection from January 2017 to November 2019 and 805 patients (68.5%) with PCA who underwent surgery from November 2014 to December 2019. The association of endogenous testosterone, which was measured before surgery, with the risk of PGD was evaluated by statistical methods. RESULTS: In the study population, endogenous testosterone levels were significantly lower in PCA cases compared to BPH patients who were older with larger prostates but lower prostate-specific antigen (PSA) levels. On multivariate analysis, the risk of PCA decreased by endogenous testosterone (odds ratio, OR = 0.957; 95% CI 0.930-0.984; p = 0.002) as by age (OR = 0.955; 95% CI 0.933-0.984; p < 0,0001) and prostate volume (OR = 0.930; 95% CI 0.919-0.940; p < 0.0001) but increased by PSA (OR = 1.652; 95% CI 1.542-1.769; p < 0.0001). On multivariate linear regression analysis, endogenous testosterone inversely associated with body mass index (BMI) (regression coefficient, b = - 0.279; p = 0.002) and PCA (b = - 2.935; p < 0.0001). CONCLUSIONS: In the aging male, endogenous testosterone independently predicted malignant prostate disorders, which associated with decreased hormone levels along BMI categories. Endogenous testosterone is a further marker for evaluating prostate growing disorders in clinical practice; however, controlled studies are required.
OBJECTIVE: To investigate the associations of endogenous testosterone with prostate growing disorders (PGD) including benign prostatic hyperplasia (BPH) and prostate cancer (PCA). METHODS: The study population was composed by 1176 cases including 371 BPH subjects (31.5%) without cancer who underwent prostate transurethral resection from January 2017 to November 2019 and 805 patients (68.5%) with PCA who underwent surgery from November 2014 to December 2019. The association of endogenous testosterone, which was measured before surgery, with the risk of PGD was evaluated by statistical methods. RESULTS: In the study population, endogenous testosterone levels were significantly lower in PCA cases compared to BPH patients who were older with larger prostates but lower prostate-specific antigen (PSA) levels. On multivariate analysis, the risk of PCA decreased by endogenous testosterone (odds ratio, OR = 0.957; 95% CI 0.930-0.984; p = 0.002) as by age (OR = 0.955; 95% CI 0.933-0.984; p < 0,0001) and prostate volume (OR = 0.930; 95% CI 0.919-0.940; p < 0.0001) but increased by PSA (OR = 1.652; 95% CI 1.542-1.769; p < 0.0001). On multivariate linear regression analysis, endogenous testosterone inversely associated with body mass index (BMI) (regression coefficient, b = - 0.279; p = 0.002) and PCA (b = - 2.935; p < 0.0001). CONCLUSIONS: In the aging male, endogenous testosterone independently predicted malignant prostate disorders, which associated with decreased hormone levels along BMI categories. Endogenous testosterone is a further marker for evaluating prostate growing disorders in clinical practice; however, controlled studies are required.
Entities:
Keywords:
Benign prostatic hyperplasia; Endogenous testosterone; Prostate cancer; Prostate growing disorders; Radical prostatectomy; Transurethral resection of the prostate
Authors: Antonio B Porcaro; Alessandro Tafuri; Marco Sebben; Marco Pirozzi; Tania Processali; Riccardo Rizzetto; Nelia Amigoni; Aliasger Shakir; Leone Tiso; Clara Cerrato; Andrea Panunzio; Mario De Michele; Maria Angela Cerruto; Matteo Brunelli; Filippo Migliorini; Salvatore Siracusano; Walter Artibani Journal: Urol Int Date: 2019-06-04 Impact factor: 2.089
Authors: Alessandro Tafuri; Marco Sebben; Marco Pirozzi; Tania Processali; Aliasger Shakir; Riccardo Rizzetto; Nelia Amigoni; Leone Tiso; Mario De Michele; Andrea Panunzio; Clara Cerrato; Filippo Migliorini; Giovanni Novella; Vincenzo De Marco; Salvatore Siracusano; Walter Artibani; Antonio Benito Porcaro Journal: Urol Int Date: 2020-01-28 Impact factor: 2.089
Authors: Antonio Benito Porcaro; Alessandro Tafuri; Andrea Panunzio; Riccardo Rizzetto; Nelia Amigoni; Clara Cerrato; Aliasger Shakir; Sebastian Gallina; Alberto Bianchi; Francesco Cianflone; Emanuele Serafin; Alessandra Gozzo; Giacomo Di Filippo; Filippo Migliorini; Giovanni Novella; Matteo Brunelli; Maria Angela Cerruto; Alessandro Antonelli Journal: Int Urol Nephrol Date: 2021-09-27 Impact factor: 2.370